Segmentation and Tracking of Tumor Vasculature Using Volumetric Multispectral Optoacoustic Tomography

2021 ◽  
pp. 75-78
Author(s):  
Agnieszka Łach ◽  
Subhamoy Mandal ◽  
Daniel Razansky
2017 ◽  
Author(s):  
Michal R. Tomaszewski ◽  
Isabel Quiros-Gonzalez ◽  
James Joseph ◽  
Sarah E. Bohndiek

2010 ◽  
Vol 35 (14) ◽  
pp. 2475 ◽  
Author(s):  
Andreas Buehler ◽  
Eva Herzog ◽  
Daniel Razansky ◽  
Vasilis Ntziachristos

Author(s):  
Emmanuel Gabriel ◽  
Minhyung Kim ◽  
Daniel Fisher ◽  
Catherine Mangum ◽  
Kristopher Attwood ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2064
Author(s):  
Piero Colombatto ◽  
Coskun Ozer Demirtas ◽  
Gabriele Ricco ◽  
Luigi Civitano ◽  
Piero Boraschi ◽  
...  

In advanced HCC, tyrosine-kinase inhibitors obtain partial responses (PR) in some patients and complete responses (CR) in a few. Better understanding of the mechanism of response could be achieved by the radiomic approach combining digital imaging and serological biomarkers (α-fetoprotein, AFP and protein induced by vitamin K absence-II, PIVKA-II) kinetics. A physic-mathematical model was developed to investigate cancer cells and vasculature dynamics in three prototype patients receiving sorafenib and/or regorafenib and applied in seven others for validation. Overall four patients showed CR, two PR, two stable-disease (SD) and two progressive-disease (PD). The rate constant of cancer cells production was higher in PD than in PR-SD and CR (median: 0.398 vs. 0.325 vs. 0.316 C × day−1). Therapy induced reduction of neo-angiogenesis was greater in CR than in PR-SD and PD (median: 83.2% vs. 29.4% and 2.0%), as the reduction of cell-proliferation (55.2% vs. 7.6% and 0.7%). An additional dose-dependent acceleration of tumor vasculature decay was also observed in CR. AFP and cancer cells followed the same kinetics, whereas PIVKA-II time/dose dependent fluctuations were influenced also by tissue ischemia. In conclusion, pending confirmation in a larger HCC cohort, modeling serological and imaging biomarkers could be a new tool for systemic therapy personalization.


Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 617
Author(s):  
Guoqing Bao ◽  
Xiuying Wang ◽  
Ran Xu ◽  
Christina Loh ◽  
Oreoluwa Daniel Adeyinka ◽  
...  

We have developed a platform, termed PathoFusion, which is an integrated system for marking, training, and recognition of pathological features in whole-slide tissue sections. The platform uses a bifocal convolutional neural network (BCNN) which is designed to simultaneously capture both index and contextual feature information from shorter and longer image tiles, respectively. This is analogous to how a microscopist in pathology works, identifying a cancerous morphological feature in the tissue context using first a narrow and then a wider focus, hence bifocal. Adjacent tissue sections obtained from glioblastoma cases were processed for hematoxylin and eosin (H&E) and immunohistochemical (CD276) staining. Image tiles cropped from the digitized images based on markings made by a consultant neuropathologist were used to train the BCNN. PathoFusion demonstrated its ability to recognize malignant neuropathological features autonomously and map immunohistochemical data simultaneously. Our experiments show that PathoFusion achieved areas under the curve (AUCs) of 0.985 ± 0.011 and 0.988 ± 0.001 in patch-level recognition of six typical pathomorphological features and detection of associated immunoreactivity, respectively. On this basis, the system further correlated CD276 immunoreactivity to abnormal tumor vasculature. Corresponding feature distributions and overlaps were visualized by heatmaps, permitting high-resolution qualitative as well as quantitative morphological analyses for entire histological slides. Recognition of more user-defined pathomorphological features can be added to the system and included in future tissue analyses. Integration of PathoFusion with the day-to-day service workflow of a (neuro)pathology department is a goal. The software code for PathoFusion is made publicly available.


Author(s):  
Lydia M. Zopf ◽  
Patrick Heimel ◽  
Stefan H. Geyer ◽  
Anoop Kavirayani ◽  
Susanne Reier ◽  
...  

AbstractTumor vasculature and angiogenesis play a crucial role in tumor progression. Their visualization is therefore of utmost importance to the community. In this proof-of-principle study, we have established a novel cross-modality imaging (CMI) pipeline to characterize exactly the same murine tumors across scales and penetration depths, using orthotopic models of melanoma cancer. This allowed the acquisition of a comprehensive set of vascular parameters for a single tumor. The workflow visualizes capillaries at different length scales, puts them into the context of the overall tumor vessel network and allows quantification and comparison of vessel densities and morphologies by different modalities. The workflow adds information about hypoxia and blood flow rates. The CMI approach includes well-established technologies such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and ultrasound (US), and modalities that are recent entrants into preclinical discovery such as optical coherence tomography (OCT) and high-resolution episcopic microscopy (HREM). This novel CMI platform establishes the feasibility of combining these technologies using an extensive image processing pipeline. Despite the challenges pertaining to the integration of microscopic and macroscopic data across spatial resolutions, we also established an open-source pipeline for the semi-automated co-registration of the diverse multiscale datasets, which enables truly correlative vascular imaging. Although focused on tumor vasculature, our CMI platform can be used to tackle a multitude of research questions in cancer biology.


Sign in / Sign up

Export Citation Format

Share Document